University of Pittsburgh

University of Tennessee Research Foundation

Pds Biotechnology Corporation

The University of North Carolina at Chapel Hill

Other

Mcmaster University

Thomas Jefferson University

Targeted Genetics Corporation

Roger Williams Medical Center

Leaf Huang

Xiang Gao

Frank L Sorgi

Frank Bedu-Addo

Richard M Epand

Remo Bottega

Gregory Conn

Elizabeth Ann Vasievich

Weihsu Claire Chen

Dexi Liu

Kenya N Toney Johnson

Michael B Chancellor

Matthew Oliver Fraser

Naoki Yoshimura

Weihsu Chen

William C De Groat

Hemant M Deshmukh

Toshifumi Hara

Weili Yan

Feng Liu

Jing-Ping Yang

Jerome Connor

Jun Li

Yao-Chi Chuang

Jennifer Rubin Grandis

Kenya Johnson

Ralph Wilfred Paul

Rihe Liu

Pradeep Tyagi

Aaron Garth Loomis

Mark A Zern

Shyh-Dar Li

Robert J Lee

Kai Shi

Yukai He

Zhengrong Cui

John Dileo

Lei Miao

Su-Ji Han

Dileep P Vangasseri

Tyler Goodwin

Kenya Toney

Hermant M Deshmukh

Tony Yoa

David L Sloane

Yunching Chen

Joyeeta Sen

Rodney J Ho

Surendar Reddy Bathula

Yi Zhao

Sumio Chono

Shutao Guo

Michael Hackett

The present invention provides compositions and methods for stimulating an immune response using cationic lipids alone or in combination with antigens.

Stimulation of an immune response by cationic lipids

A composition and method for activating immune cells ex-vivo, or inducing an immune response in a subject including a composition comprising at least one chiral cationic lipid. The chiral cationic lipid in one embodiment comprises a nonsteroidal cationic lipid having a structure represented by formula (I); wherein in Ris a quaternary ammonium group, Yis a space chosen from a hydrocarbon chain, an ester, a ketone, and a peptide, C* is a chiral carbon, Rand Rare independently chosen from a saturated fatty acid, an unsaturated fatty acid, an ester-linked hydrocarbon, phosphor-diesters, and combination thereof.

Stimulation of an immune response by enantiomers of cationic lipids

The subject matter described herein is directed to methods of modifying the micro-environment of a target cell or The methods comprise systemically administering to a subject a composition comprising a vector, wherein the vector comprises a construct for the expression of a trap in the target cell, wherein the trap is expressed in the target cell thereby modifiying the micro-environment. Also described herein are methods of reducing metastasis of a cancer comprising, systemically administering to a subject suffering from the cancer, a composition comprising a vector, wherein the vector comprises a construct for the expression of a trap, wherein the trap is delivered to and then expressed in tissue susceptible to metastasis, wherein metastasis of the cancer to the tissue is reduced. Compositions for carrying out the methods are also described.

Methods and compositions for reducing metastases

A composition and method for activating immune cells ex-vivo, or inducing an immune response in a subject including a composition comprising at least one chiral cationic lipid. The chiral cationic lipid in one embodiment comprises a nonsteroidal cationic lipid having a structure represented by formula (I); wherein in Ris a quaternary ammonium group, Yis a spacer chosen from a hydrocarbon chain, an ester, a ketone, and a peptide, C* is a chiral carbon, Rand Rare independently chosen from a saturated fatty acid, an unsaturated fatty acid, an ester-linked hydrocarbon, phosphor-diesters, and combinations thereof.

Provided herein are methods and compositions for the delivery of bioactive compounds to a cell, tissue, or physiological site. The compositions comprise delivery system complexes comprising liposomes encapsulating a biodegradable ionic precipitate having incorporated therein a bioactive compound and delivery system complexes comprising a biodegradable ionic precipitate ionically bound to a surrounding lipid bilayer, wherein the biodegradable ionic precipitate comprises a bioactive compound. Also provided herein are methods for the treatment of a disease or an unwanted condition in a subject, wherein the methods comprise administering the delivery system complexes comprising bioactive compounds that have therapeutic activity against the disease or unwanted condition to the subject.

Liposomes comprising a calcium phosphate-containing precipitate

Provided herein are polymers comprising Metformin residues ('PolyMet') as useful therapeutic agents, delivery vehicles and transfection agents for nucleotides. Also provided herein are methods for the treatment of a disease or an unwanted condition in a subject, wherein the methods comprise administering PolyMet as a therapeutic agent to combat the disease or condition. Also provided herein are methods for the treatment of a disease or an unwanted condition in a subject, wherein the methods comprise administering a therapeutic agent in a delivery vehicle that comprises PolyMet. Further provided herein are methods for making PolyMet.

Polymeric metformin and its use as a therapeutic agent and as a delivery vehicle

Compositions and methods for treating immune cells and activating immune responses are disclosed. The compositions comprise one or more optically active chiral cationic lipids.

Novel stable, concentrated, biologically active and ready-to-use lipid-comprising drug delivery complexes and methods for their production are described. The biological activity of the complexes produced are comparable to the formulations prepared according to the prior art admixture method and upon purification, the complexes produced by the method of this invention are 50 to 500 fold more concentrated than the complexes formed by admixture. The method described herein provides for the large scale production of lipid-comprising drug delivery systems useful for gene therapy and other applications.

Stable lipid-comprising drug delivery complexes and methods for their production

Provided herein are novel cationic lipids, compositions comprising the cationic lipids, and methods of using the cationic lipids. In some claims, the cationic lipids have cytotoxic activity and can be used alone or in combination with a cytotoxic bioactive compound to kill a cell. In some of these claims, the cationic lipid enhances the cytotoxic activity of the cytotoxic bioactive compound. Methods for treating a subject afflicted with a disease or unwanted condition are provided, wherein the method comprises administering a delivery system comprising a novel cationic lipid to the subject. The invention further provides methods for making delivery systems comprising the novel cationic lipids of the invention.

Methods and compositions comprising novel cationic lipids

The present invention provides pharmaceutical compositions and methods for the instillation of lipid vehicles comprised of liposomes containing sphingomyelin or sphingomyelin metabolites to prevent, manage, ameliorate and/or treat disorders involving neuropathic pain and aberrant muscle contractions, such as what occurs in bladder hyperactivity disorders such as interstitial cystitis (IC) in animals or humans in need thereof. Also provided is a liposome-based delivery of drugs, e.g., antibiotics, pain treatments and anticancer agents, to the bladder, genitourinary tract, gastrointestinal system, pulmonary system and other organs or body systems. In particular, liposome-based delivery of vanilloid compounds, such as resiniferatoxin, capsaicin, or tinyatoxin and toxins, such as botulinum toxin is provided for the treatment of bladder conditions, including pain, inflammation, incontinence and voiding dysfunction.

Sphingomyelin liposomes for the treatment of hyperactive bladder disorders

A nucleic acid is provided comprising an expression cassette which includes transcription control sequences of a member of a class of Pol III-transcribed genes in which no transcribed portion of the Pol III gene is required for transcription of the gene. In the expression cassette, the transcribed 5' hairpin structure of the Pol III gene is deleted. The transcription control sequences are operably linked to a sequence of an EGFR gene in an antisense orientation suitable for decreasing expression of EGFR in the cell when transcribed. Lastly, a method for decreasing expression of EGFR in cells is provided that includes the step of contacting target cells either parenterally or directly into the tumor or tissue adjacent to the tumor cells with the nucleic acid of the present invention.

Inhibition of human squamous cell carcinoma growth in vivo by epidermal growth factor receptor antisense RNA transcribed from a Pol III promoter

Growing community of inventors

Durham, NC, United States of America

Leaf Huang